Zyrtec-D Paragraph IV Application Submitted To FDA
This article was originally published in The Tan Sheet
A generic version of Pfizer's Zyrtec-D 12 Hour is among the Paragraph IV abbreviated new drug applications submitted to FDA early this summer
You may also be interested in...
An orally disintegrating strip form of Johnson & Johnson/Merck's Pepcid AC (famotidine 10 mg) could be heading towards the market if FDA looks favorably upon a pending ANDA suitability petition
Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company
A recent regulatory submission filed with FDA is seeking 180-day exclusivity for a generic version of nicotine replacement therapy lozenges